Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2

Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2

Publication: PLoS One
Software: GastroPlus®

SHetA2 is a small molecule drug with promising cancer prevention and therapeutic activity and a high preclinical safety profile. The study objectives were to perform interspecies scaling and...

Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report

Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report

Publication: AAPS J
Software: GastroPlus®
Division: PBPK

On May 15th–17th, 2017, the US FDA and the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) held a workshop at the University of Maryland’s Center of Excellence...

Mechanistic Absorption/PBPK Modeling to Predict Positive/Negative Food Effects: Approaches and Special Considerations

Mechanistic Absorption/PBPK Modeling to Predict Positive/Negative Food Effects: Approaches and Special Considerations

Authors: DiBella J
Conference: Le Club Phase 1 PBPK Symposium
Division: PBPK

1) Early examples and proposed approach 2) Fasted vs. fed state model descriptions – where are we today? 3) Case study: positive food effect predictions – input review 4) Case study: negative food effect…

Leveraging PopPK and PBPK Modeling Approaches to Understand Food/PPI Effects

Leveraging PopPK and PBPK Modeling Approaches to Understand Food/PPI Effects

Authors: DiBella J
Conference: Le Club Phase 1 PBPK Symposium
Division: PBPK

Applying both top-down (PopPK and PBPK) and bottom-up (PBPK) modeling approaches can leverage existing data sets and help prospectively answer questions. Predictions of absorption-related DDIs…

A strategy for early risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors

A strategy for early risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors

Publication: Xenobiotica
Software: GastroPlus®

A set of reference compounds for time-dependent inhibition (TDI) of cytochrome P450 with available literature data for kinact and KI was used to predict clinical implications using the GastroPlusTM software.

Discovery PBPK: How to enhance the expected accuracy of bioavailability predictions for NCEs that are not primarily metabolized

Discovery PBPK: How to enhance the expected accuracy of bioavailability predictions for NCEs that are not primarily metabolized

Authors: Martin EJ, Bolger MB
Division: PBPK

In this webinar, we will review the accuracy of purely in silico estimates of bioavailability and the chemistry classification of new chemical entity (NCE) molecules that are easier or harder to...

Experimental versus theoretical log D7.4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances

Experimental versus theoretical log D7.4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances

Publication: Drug Test Anal
Software: ADMET Predictor®

The misuse of benzodiazepines as new psychoactive substances is an increasing problem around the world. Basic physicochemical and pharmacokinetic data is required on these substances to interpret and predict their effects upon humans.

Abatacept Population Pharmacokinetics and Exposure-Response Analyses for Dose Recommendation of SC and IV Abatacept in Patients With Psoriatic Arthritis

Abatacept Population Pharmacokinetics and Exposure-Response Analyses for Dose Recommendation of SC and IV Abatacept in Patients With Psoriatic Arthritis

Conference: ASCPT

Both subcutaneous (SC) and intravenous (IV) abatacept, a selective T-cell co-stimulation modulator, are approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) and...

Case Study in Placebo Modeling and Its Effect on Drug Development

Case Study in Placebo Modeling and Its Effect on Drug Development

Authors: Passarell JA
Conference: ASCPT

ADHD (attention-deficit/hyperactivity disorder) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity associated with clinically significant impairment in functioning.

Walt Woltosz on the passing of world-famous astrophysicist, Professor Sir Stephen Hawking

Walt Woltosz on the passing of world-famous astrophysicist, Professor Sir Stephen Hawking

Walt Woltosz, chairman of Simulations Plus Inc., commented on the passing of world-famous astrophysicist, Professor Sir Stephen Hawking...
"Stephen Hawking was a remarkable man and a global scientific leader. But he was also charming and witty, with a nice sense of humor. He would "dance" in his electric wheelchair at festive events, spinning in circles and dazzling all who watched. He made his place in history, along with Newton, Einstein, Bohr, and so many others. He will be missed."